Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719418 | 0.85 | KCNH2 (0.52) | MCL1KDM4EKCNH2HPGDSMN1; SMN2 | |
| SCHEMBL10514760 | 0.85 | NPC1 (0.55) | MCL1KDM4EKCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL7386021 | 0.83 | HIF1A (0.54) | KDM4EKCNH2ALDH1A1TSHR | |
| SCHEMBL8713025 | 0.81 | KDM4E (0.42) | MCL1KDM4EGPR35KCNH2HPGD | |
| SCHEMBL1065472 | 0.79 | MCL1 (0.71) | MCL1KDM4EGPR35KCNH2HPGD | |
| SCHEMBL5287590 | 0.78 | MCL1 (0.69) | MCL1KDM4EGPR35KCNH2HPGD | |
| SCHEMBL10163685 | 0.77 | CDK9 (0.46) | KCNH2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7392628 | 0.77 | PTGER4 (0.40) | MCL1KDM4EGPR35ALDH1A1 | |
| SCHEMBL4615856 | 0.76 | MCL1 (1.00) | MCL1KDM4EGPR35KCNH2HPGD | |
| SCHEMBL4310466 | 0.76 | MCL1 (0.67) | MCL1KDM4EGPR35HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KDM4E 1907/4885GPR35 2417/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KDM4E 1907/4885GPR35 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.